01Jul
Novartis and Alcon FCPA Enforcement Action: Lessons Learned (Part III of III)
At the outset, Novartis is “lucky” – the settlement is relatively positive, despite its 2016 SEC enforcement action in China. Given Novartis weak culture of compliance (if anything, a better description may be a culture of non-compliance) and its status as a recidivist, Novartis could have been slammed with a stiffer enforcement action, including assignment of an independent corporate compliance monitor and a higher penalty. ...
By:
Michael Volkov
Related
Employees with Disabilities Denied Reasonable Accommodations, Federal Agency Charges - Newburgh, N...
Read More >
In a landmark decision, a Pennsylvania jury ruled in favor of the defendant National Collegiate Athl...
Read More >
One of the hardest areas of M&A due diligence is the target company’s technology. The buyer has to...
Read More >
Although the construction industry was generally exempted from Governor Jim Justice’s March 23, 202...
Read More >
CSG Labor & Employment Alert - The U.S. Department of Labor’s Occupational Safety and Health Admin...
Read More >
COVID-19 travel restrictions have put the aviation industry on the backfoot. M&A will not be an imme...
Read More >